{
    "nct_id": "NCT06590961",
    "official_title": "A Phase Ia/Ib, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic of UBX-303061 in Subjects with Relapsed/Refractory B-Cell Malignancies",
    "inclusion_criteria": "Key Inclusion Criteria\n\n* Capable of giving signed informed consent\n* Age ≥18 years\n* ECOG performance status ≤2.\n* Phase Ia (dose-escalation part only): Subjects with relapsed and/or refractory B-cell malignancies (CLL/SLL, DLBCL, FL, MCL, WM or MZL) who have received at least 2 prior therapies and for subjects with no available treatment options as per the Investigator's discretion.\n* Phase Ib (dose-expansion only): Subjects with relapsed and/or refractory B-cell malignancies who have received at least 2 prior therapies and for subjects with no available treatment options as per the Investigator's discretion, and fit into one of the following groups: CLL/SLL or DLBCL or MCL or FL, WM, MZL\n* All subjects must have evaluable or measurable disease based on the appropriate tumor type criteria\n* Adequate organ and bone marrow function\n\nKey Exclusion Criteria\n\n* For subjects with lymphoma:\n\n  * Systemic antineoplastic therapy or any experimental therapy within 3 weeks or 5 half-lives, whichever is shorter, before the first dose of study treatment.\n  * Therapy with tyrosine kinase inhibitor within 5 half-lives before the first dose of study treatment.\n  * Unconjugated monoclonal antibody therapies <6 weeks before the first dose of study treatment.\n  * Subjects that have undergone autologous stem cell rescue within 100 days prior to the first dose of study treatment.\n  * Subjects that have undergone allogeneic stem cell transplant within 6 months prior to the first dose of study treatment.\n  * Subjects with active graft-versus-host disease (GVHD) or on anti-GVHD treatment or prophylaxis.\n  * History of chimeric antigen receptor T cell (CAR-T) therapy within 100 days prior to start of study drug.\n  * Any immunotherapy within 4 weeks of first dose of study drug.\n  * The time from the last dose of the most recent chemotherapy or experimental therapy to the first dose of study drug is <5 times the t1/2 of the previously administered agent(s).\n* Previously exposed to BTK degradation therapy\n* Malignant disease, other than that being treated in this study.\n* Radiotherapy within 2 weeks of the first dose of study treatment\n* Known hypersensitivity to BTK degraders or any of the ingredients.\n* Impaired cardiac function or clinically significant cardiac disease\n* Subjects with history of severe bleeding disorders and known/suspected other autoimmune disease\n* Major surgery within 4 weeks of the first dose of study treatment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}